Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

10 Best Healthcare Stocks to Buy for the Long Term 

Page 1 of 4

In this article, we will look at the 10 Best Healthcare Stocks to Buy for the Long Term. 

On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived, especially when compared to the bigger and long-term worries for the market, such as concerns over capex spend and the AI boom.

He was of the view that we should always look back into history, as it is very easy to get swayed by and caught up in the emotions of what is happening in the short term. The reality, he stated, is that wars have a very limited long-term impact on stock markets. While we will see some effects, with some sectors affected more than others, the long-term impact is usually relatively short-lived, which is why he is trying to look through that.

READ ALSO: 10 Best Performing Healthcare Stocks So Far in 2026 AND 10 Best Strong Buy Stocks to Invest in According to Billionaires

Bathgate further stated that before we entered into this war, the US stock markets had been accelerating into the tail end of last year. Therefore, he is trying to assess the long-term nature of what happens with AI, energy supply, and long-term drivers of underlying profitability in the markets, which is driven by things that are very different from what we are seeing in the Middle East at the moment.

With these broader market trends in view, let’s narrow down and look at the best healthcare stocks to buy for the long term.

Our Methodology

We used the Finviz stock screener to identify the best high-growth healthcare stocks with a forward P/E below 15 and selected the top 10 stocks most popular among hedge funds as of Q4 2025, using the hedge fund sentiment data from Insider Monkey’s database. The stocks are arranged in ascending order of hedge fund sentiment.

Note: All data was recorded on May 8.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Best Healthcare Stocks to Buy for the Long Term 

10. AdaptHealth Corp. (NASDAQ:AHCO)

Number of Hedge Fund Holders: 22

AdaptHealth Corp. (NASDAQ:AHCO) is one of the best healthcare stocks to buy for the long term. Canaccord lifted the price target on AdaptHealth Corp. (NASDAQ:AHCO) to $16 from $14 on May 7, reiterating a Buy rating on the shares. The firm updated its model after the company released its fiscal Q1 results, where EBITDA missed estimates and caused a pullback in the shares. It added that AdaptHealth Corp. (NASDAQ:AHCO) appears to be uniquely positioned in the DME market to gain share, especially if the demand environment for capitated agreements becomes the preferred method to better serve patients with chronic conditions.

AdaptHealth Corp. (NASDAQ:AHCO) released its fiscal Q1 2026 results on May 5, with net revenue for the quarter coming up to $819.8 million compared to $777.9 million, reflecting an increase of 5.4%. The company also reported organic revenue growth of 9.1%, with growth across each of the reportable segments. Net loss attributable to the company was $16.0 million.

AdaptHealth Corp. (NASDAQ:AHCO) provides home healthcare equipment, supplies, and related services. The company’s focus is on sleep therapy equipment for obstructive sleep apnea, oxygen, and related chronic therapy services, HME medical devices and supplies for wound care, diabetes, urological, and more.

9. ​Phibro Animal Health Corporation (NASDAQ:PAHC)

Number of Hedge Fund Holders: 25

Phibro Animal Health Corporation (NASDAQ:PAHC) is one of the best healthcare stocks to buy for the long term. Phibro Animal Health Corporation (NASDAQ:PAHC) announced on May 6 financial results for its third quarter ended March 31, 2026, along with updated financial guidance for the year ending June 30, 2026. The company reported net sales of $383.5 million for the quarter, reflecting an increase of $35.7 million, or 10%, from the prior year period. Net income reached $24.0 million, an increase of $3.1 million, or 15%, with diluted earnings per share of $0.59, an increase of $0.08, or 16% from the prior year period.

Phibro Animal Health Corporation (NASDAQ:PAHC) attributed the positive results to continued strength in the company’s Animal Health business, where sales rose 13%, backed by strong demand across MFAs, vaccines, and nutritional specialties. The company also updated its fiscal year 2026 guidance, which includes net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million.

Phibro Animal Health Corporation (NASDAQ:PAHC) develops, manufactures, and markets animal health and mineral nutrition products. Its operations are divided into the following segments: Animal Health, Mineral Nutrition, and Performance Products.

Page 1 of 4

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.